Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $68.29, indicating a -6.54% shift from the previous trading day.

Crispr Therapeutics AG ( ($CRSP) ) has issued an update. On October 15, 2025, CRISPR Therapeutics AG announced the filing of a prospectus ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving -2.46% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.28% for ...

In this article, we will take a look at the 14 Best Biotech Stocks to Buy Right Now. The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

The presentation will introduce the Company’s novel SyNTase gene editing technology and highlight its application ... are the property of their respective owners. CRISPR Therapeutics NewsMORE Related ...

Crispr Therapeutics AG remains undervalued despite recent stock volatility and slow Casgevy commercial uptake, with long-term potential intact. Casgevy's strong clinical data and broad approvals are ...

Since 2019, MIT researchers have published a new concept called prime editing, which is more precise than regular CRISPR-Cas9 gene editing. As a result, it has fewer off-target effects and less chance ...

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...